M Ali R M K, England A, McEntee M F, Mercer C E, Tootell A, Hogg P
University of Kufa, Iraq; University of Salford, UK.
University of Salford, UK.
Radiography (Lond). 2018 Aug;24(3):240-246. doi: 10.1016/j.radi.2018.02.001. Epub 2018 Mar 15.
The performance of mammography screening programmes is focussed mainly on breast cancer detection rates. However, when the benefits and risks of mammography are considered, the risk of radiation-induced cancer is calculated for only the examined breast using Mean Glandular Dose (MGD). The risk from radiation during mammography is often described as low or minimal. This study aims to evaluate the effective lifetime risk from full field digital mammography (FFDM) for a number of national screening programmes.
Using an ATOM phantom, radiation doses to multiple organs were measured during standard screening mammography. Sixteen FFDM machines were used and the effective lifetime risk was calculated across the female lifespan for each machine. Once the risks were calculated using the phantom, the total effective lifetime risk across 48 national screening programmes was then calculated; this assumed that all these programmes use FFDM for screening.
Large differences exist in effective lifetime risk, varying from 42.21 [39.12-45.30] cases/10 (mean [95% CI]) in the Maltese screening programme to 1099.67 [1019.25-1180.09] cases/10 for high breast cancer risk women in the United States of America. These differences are mainly attributed to the commencement age of screening mammography and the time interval between successive screens.
Effective risk should be considered as an additional parameter for the assessment of screening mammography programme performance, especially for those programmes which recommend an early onset and more frequent screening mammography.
乳腺钼靶筛查项目的成效主要集中在乳腺癌检出率上。然而,在考量乳腺钼靶检查的益处与风险时,仅使用平均腺体剂量(MGD)来计算受检乳房因辐射诱发癌症的风险。乳腺钼靶检查期间的辐射风险通常被描述为低风险或极小风险。本研究旨在评估多个国家筛查项目中全视野数字乳腺钼靶(FFDM)带来的有效终生风险。
使用ATOM体模,在标准筛查乳腺钼靶检查期间测量多个器官的辐射剂量。使用了16台FFDM机器,并计算了每台机器在女性整个生命周期内的有效终生风险。在使用体模计算出风险后,接着计算了48个国家筛查项目的总有效终生风险;这假定所有这些项目都使用FFDM进行筛查。
有效终生风险存在很大差异,从马耳他筛查项目中的42.21[39.12 - 45.30]例/10(均值[95%置信区间])到美国乳腺癌高风险女性中的1099.67[1019.25 - 1180.09]例/10。这些差异主要归因于筛查乳腺钼靶检查的起始年龄以及连续筛查之间的时间间隔。
有效风险应被视为评估乳腺钼靶筛查项目成效的一个额外参数,尤其是对于那些建议早期开始且更频繁进行筛查乳腺钼靶检查的项目。